Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Overview of Sensus Healthcare Inc
Sensus Healthcare Inc is a specialized medical device company that has dedicated over a decade to the development of non-invasive treatment solutions using proprietary superficial radiation therapy (SRT) technology. This innovative treatment method is designed for both oncological and non-oncological skin conditions, including various forms of non-melanoma skin cancers and conditions such as keloids, offering a safe and cost-effective alternative to surgical procedures.
Core Technology and Treatment Solutions
The company utilizes a proprietary low energy x-ray radiation system that underpins its SRT technology. This method enables precise targeting of skin lesions while minimizing damage to surrounding tissues. The approach is rooted in extensive research and development, ensuring that each device deployed not only aligns with current clinical standards but also supports a streamlined treatment process. The primary devices in the company’s portfolio are designed to simplify the treatment procedure while ensuring efficacy and patient safety.
Business Model and Revenue Generation
Sensus Healthcare Inc generates revenue primarily through the sale of its specialized SRT treatment devices alongside an associated service program. The revenue model is based on direct transactions with hospitals, oncology centers, and dermatology practices, particularly in the United States. The company’s sales approach integrates product delivery with ongoing support, positioning Sensus as a comprehensive service provider within the medical device industry. This dual-focus on advanced technology and customer service ensures that clients receive not only the equipment but also the necessary operational expertise to maximize treatment outcomes.
Market Position and Industry Significance
Operating within the competitive realm of medical devices, Sensus Healthcare Inc has carved out a niche by focusing on non-invasive superficial radiation therapy. The technology addresses a clear need in the treatment of skin conditions by reducing the potential risks and complications associated with more invasive procedures. With increasing emphasis on patient safety and cost-effectiveness in healthcare, the company’s offerings are well-positioned to provide value within hospital oncology and dermatology departments. Its emphasis on targeted radiation treatment distinguishes its operational approach from other modalities available in the market.
Operational Focus and Customer Base
The company's operational framework is built around delivering effective treatment solutions through both its high-quality devices and a robust support program. The customer base includes major healthcare providers such as hospital oncology departments and specialized dermatology practices. By prioritizing reliability and clinical efficacy, Sensus Healthcare sustains trust within the medical community, ensuring continuous adoption of its technology in outpatient treatment settings.
Clinical Impact and Safety
At the heart of Sensus Healthcare Inc's offerings is a strong commitment to patient safety and treatment efficacy. The non-invasive SRT technique minimizes the need for surgical intervention, thereby reducing recovery times and potential risks associated with more invasive treatments. This clinical approach not only enhances patient outcomes but also supports operational efficiency in healthcare settings by offering a streamlined alternative that aligns with modern treatment protocols.
Competitive Landscape and Differentiation
Sensus Healthcare Inc operates in a dynamic industry where differentiation is critical. The company sets itself apart through its exclusive focus on superficial radiation therapy, a technology with a clear evidential basis in decades of research and clinical application. Although facing competition from traditional and emerging treatment modalities, Sensus leverages its research-backed technology and dedicated service programs to maintain a distinct foothold in the market. Expertise in both technological innovation and customer service elevates its competitive profile as a trusted provider in the non-invasive medical device segment.
Conclusion
In summary, Sensus Healthcare Inc is a specialized medical device entity that combines technological innovation with secure, non-invasive treatment options. Its use of superficial radiation therapy not only underscores advances in medical device innovation but also reflects the company's commitment to enhancing patient care in the treatment of skin conditions. This comprehensive approach, integrating advanced product development with dedicated service programs, positions Sensus Healthcare as a valued participant in a complex and critical segment of healthcare technology.
Sensus Healthcare reported an 83% revenue increase year-over-year, achieving $3.1 million in the first quarter of 2021 compared to $1.7 million in 2020. The company installed its 500th unit and narrowed its net loss to $1.1 million or $0.07 per share, down from $3.6 million or $0.22 per share last year. Gross profit rose to $1.6 million, with a gross margin of 51.6%. Cash and equivalents totaled $13.7 million as of March 31, 2021. Management anticipates continued revenue growth driven by higher reimbursement rates and expanding market acceptance.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a conference call on May 6, 2021, at 4:30 p.m. Eastern Time to discuss its Q1 2021 financial results and provide a business update. The call will be accessible via dial-in numbers (888-390-3967 for U.S. and Canada; 862-298-0702 for international) and a live webcast. Sensus Healthcare specializes in non-invasive medical devices for oncological and non-oncological conditions, including the Sculptura™ system and SRT-100™ technology for skin cancer treatments, emphasizing innovation in patient care.
Sensus Healthcare (Nasdaq: SRTS) announced a significant milestone as its SRT-100™ system successfully treated its first canine patient, Daisy, at Colorado State University's Flint Animal Cancer Center. Daisy had two mast cell tumors that were reduced after six treatments, avoiding surgery. This landmark event highlights Sensus's innovations in superficial radiation therapy (SRT), expanding the potential use of their technology in veterinary medicine. The partnership aims to develop treatment protocols and publish clinical data, promoting the commercial viability of SRT-100 in a new market.
Sensus Healthcare, Inc. (NASDAQ: SRTS), a leader in innovative medical devices, announced participation in three virtual investment conferences in March 2021. Key events include the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, the Roth Conference featuring a live panel on March 16, and the Maxim Group Emerging Growth Conference on March 17-18. These conferences offer opportunities for one-on-one meetings with institutional investors. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, enhancing patient care globally.
Sensus Healthcare (SRTS) reported a fourth-quarter net income of $1.0 million on revenues of $5.1 million, down from $8.5 million in Q4 2019. Despite shipping 18 systems, including sales in China, the revenue drop is attributed to COVID-19 impacts. The company achieved a 63.4% gross profit margin. Major highlights include increased Medicare reimbursement rates and promising clinical studies on superficial radiation therapy (SRT) for keloid treatment. The company's cash reserves stood at $14.9 million as of December 31, 2020, with a focus on recovery in the upcoming year.
Sensus Healthcare has received U.S. Patent No. 10,607,802 B2 for its Sculptura™ radiation therapy technology, enhancing treatment for all solid tumors. This patent covers the innovative beam splitting and sculpting capabilities, which are crucial for targeted therapies. The company has now secured five patents since early 2020. CEO Joe Sardano emphasized the potential for licensing this technology beyond Sculptura. The firm specializes in non-invasive treatment options and is dedicated to improving cancer care and patient quality of life.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on February 25, 2021, at 4:30 p.m. ET to discuss its Q4 2020 financial results and provide a business update on recent and upcoming milestones. The call can be accessed via dial-in numbers and will also be available as a live webcast. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, including its Sculptura™ system for cancer therapy and SRT-100™ for non-melanoma skin cancers.
Sensus Healthcare (Nasdaq: SRTS) announced that Holy Name Medical Center in New Jersey has acquired its low-dose radiation therapy system to treat pneumonia in COVID-19 patients. This portable solution allows for bedside treatment, minimizing potential exposure for patients. Preliminary data suggest a positive therapeutic effect on COVID pneumonia. CEO Joe Sardano expressed optimism about the partnership, emphasizing Holy Name's success with investigational therapies. Sensus's technology, including the SRT-100+™ and SRT-100 Vision™, offers a promising new tool during the pandemic.
Sensus Healthcare (Nasdaq: SRTS) has entered an exclusive distribution agreement with Ekpac Healthcare Ltd. for the SRT-100™ systems in China and Hong Kong, effective January 1, 2021. This agreement aims to enhance the delivery of non-invasive treatment for non-melanoma skin cancer and keloids. With 40 units currently installed across various medical facilities, Sensus anticipates significant growth in unit installations in the region. Ekpac Healthcare brings over a century of experience in the market and will leverage its distribution network to achieve sales success for these advanced medical devices.
Sensus Healthcare announces a significant change in reimbursement for Radiation Treatment Delivery code 77401, set to increase by 66% to approximately $41 per treatment, effective January 1, 2021. This increase is the first major adjustment since 2002. In addition, related Evaluation & Management codes will also see double-digit percentage increases. This development follows a concerted effort by Sensus and healthcare advocates to secure fairer payments for Superficial Radiation Therapy (SRT), a non-invasive treatment for skin cancer.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
What is the primary focus of Sensus Healthcare Inc?
How does Sensus Healthcare generate its revenue?
What skin conditions are treated with the company's technology?
What distinguishes Sensus Healthcare's technology from traditional treatment options?
Who typically uses Sensus Healthcare's treatment devices?
How does Sensus Healthcare position itself against competitors?
